Cai Yi, Dodhia Sonam, Su Gloria H
Department of Otolaryngology-Head and Neck Surgery, Columbia University Medical Center, New York, NY, USA.
Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY, USA.
Oncotarget. 2017 Mar 28;8(13):22203-22217. doi: 10.18632/oncotarget.14729.
The phosphoinositide 3-kinase (PI3K) signaling pathway is the most commonly mutated pathway in head and neck squamous cell carcinoma (HNSCC). There are several drugs targeting members of the PI3K signaling pathway in development for HNSCC. In this article, we review the genetic alterations reported in the pathway pertinent to HNSCC, various agents in development targeting various mediators of the pathway, results from clinical trials, and remaining challenges in the development of PI3K pathway inhibitors.
磷酸肌醇3激酶（PI3K）信号通路是头颈部鳞状细胞癌（HNSCC）中最常发生突变的信号通路。目前有几种针对PI3K信号通路成员的药物正处于针对HNSCC的研发阶段。在本文中，我们综述了与HNSCC相关的该信号通路中已报道的基因改变、针对该信号通路不同介质的各种研发中的药物、临床试验结果以及PI3K通路抑制剂研发中尚存的挑战。
